Table of Content

1 INTRODUCTION (Page No. - 34)
    1.1 STUDY OBJECTIVES
    1.2 MARKET DEFINITION
           1.2.1 INCLUSIONS & EXCLUSIONS
    1.3 STUDY SCOPE
           1.3.1 LIQUID BIOPSY MARKET
           1.3.2 REGIONAL SCOPE
           1.3.3 YEARS CONSIDERED
    1.4 CURRENCY
    1.5 LIMITATIONS
    1.6 STAKEHOLDERS
    1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 40)
    2.1 RESEARCH DATA
    2.2 RESEARCH APPROACH
          FIGURE 1 LIQUID BIOPSY MARKET: RESEARCH DESIGN METHODOLOGY
           2.2.1 SECONDARY DATA
                    2.2.1.1 Key data from secondary sources
           2.2.2 PRIMARY DATA
                    2.2.2.1 Primary sources
                    2.2.2.2 Key data from primary sources
                    2.2.2.3 Key industry insights
                    2.2.2.4 Breakdown of primary interviews
                                FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
                                FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
    2.3 MARKET SIZE ESTIMATION
           2.3.1 BOTTOM-UP APPROACH
                    2.3.1.1 Approach 1: Company revenue estimation approach
                                FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
                    2.3.1.2 Approach 2: Presentations of companies and primary interviews
                    2.3.1.3 CAGR projections
                                FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
           2.3.2 TOP-DOWN APPROACH
                    FIGURE 6 LIQUID BIOPSY MARKET: TOP-DOWN APPROACH
    2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
          FIGURE 7 DATA TRIANGULATION METHODOLOGY
    2.5 MARKET SHARE
    2.6 STUDY ASSUMPTIONS
    2.7 GROWTH RATE ASSUMPTIONS
    2.8 RISK ASSESSMENT
           2.8.1 RISK ASSESSMENT: LIQUID BIOPSY MARKET

3 EXECUTIVE SUMMARY (Page No. - 52)
    FIGURE 8 LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2022 VS. 2027 (USD MILLION)
    FIGURE 9 LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2022 VS. 2027 (USD MILLION)
    FIGURE 10 LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION)
    FIGURE 11 LIQUID BIOPSY MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
    FIGURE 12 LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2022 VS. 2027 (USD MILLION)
    FIGURE 13 LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2022 VS. 2027 (USD MILLION)
    FIGURE 14 LIQUID BIOPSY MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
    FIGURE 15 LIQUID BIOPSY MARKET, BY REGION, 2022 VS. 2027 (USD MILLION)

4 PREMIUM INSIGHTS (Page No. - 58)
    4.1 LIQUID BIOPSY MARKET OVERVIEW
          FIGURE 16 RISING INCIDENCE OF CANCER TO DRIVE GROWTH IN LIQUID BIOPSY MARKET
    4.2 LIQUID BIOPSY MARKET SHARE, BY PRODUCT & SERVICE, 2022 VS. 2027
          FIGURE 17 ASSAY KITS TO CONTINUE TO DOMINATE LIQUID BIOPSY MARKET DURING FORECAST PERIOD
    4.3 LIQUID BIOPSY MARKET SHARE, BY CIRCULATING BIOMARKER, 2022 VS. 2027
          FIGURE 18 CIRCULATING TUMOR CELLS TO CONTINUE TO DOMINATE MARKET IN 2027
    4.4 LIQUID BIOPSY MARKET SHARE, BY CLINICAL APPLICATION, 2022 VS. 2027
          FIGURE 19 THERAPY SELECTION SEGMENT TO HOLD LARGEST SHARE OF MARKET DURING FORECAST PERIOD
    4.5 LIQUID BIOPSY MARKET SHARE, BY TECHNOLOGY, 2022 VS. 2027
          FIGURE 20 MULTI-GENE PARALLEL ANALYSIS USING NGS SEGMENT TO HOLD LARGER SHARE OF MARKET IN 2027
    4.6 LIQUID BIOPSY MARKET SHARE, BY APPLICATION, 2022 VS. 2027
          FIGURE 21 CANCER APPLICATIONS TO LEAD MARKET IN 2027
    4.7 LIQUID BIOPSY MARKET SHARE, BY SAMPLE TYPE, 2022 VS. 2027
          FIGURE 22 BLOOD TYPE SEGMENT TO CONTINUE TO DOMINATE MARKET IN 2027
    4.8 LIQUID BIOPSY MARKET SHARE, BY END USER, 2022 VS. 2027
          FIGURE 23 REFERENCE LABORATORIES TO DRIVE MARKET GROWTH IN 2027
    4.9 LIQUID BIOPSY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
          FIGURE 24 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN LIQUID BIOPSY MARKET DURING FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 63)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
          FIGURE 25 LIQUID BIOPSY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Rising incidence and prevalence of cancer
                                TABLE 1 NUMBER OF PREVALENT CANCER CASES WORLDWIDE IN 2020, BY TYPE OF CANCER
                    5.2.1.2 Cancer awareness initiatives undertaken by global health organizations
                    5.2.1.3 Increasing preference for non-invasive treatment procedures
           5.2.2 RESTRAINTS
                    5.2.2.1 Lower sensitivity of certain liquid biopsy procedures
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Growing significance of companion diagnostics
                    5.2.3.2 Growth opportunities in emerging countries
           5.2.4 CHALLENGES
                    5.2.4.1 Unclear reimbursement scenario
    5.3 PRICING ANALYSIS
          TABLE 2 AVERAGE SELLING PRICES OF KEY PLAYERS, BY PRODUCT
          TABLE 3 AVERAGE SELLING PRICE TREND
    5.4 PATENT ANALYSIS
          FIGURE 26 PATENT ANALYSIS OF LIQUID BIOPSY
          TABLE 4 PATENT ANALYSIS
    5.5 VALUE CHAIN ANALYSIS
          FIGURE 27 MAJOR VALUE ADDITION DURING MANUFACTURING & ASSEMBLY PHASE
    5.6 SUPPLY CHAIN ANALYSIS
          FIGURE 28 LIQUID BIOPSY MARKET: SUPPLY CHAIN ANALYSIS
    5.7 ECOSYSTEM ANALYSIS OF LIQUID BIOPSY MARKET
          FIGURE 29 LIQUID BIOPSY MARKET: ECOSYSTEM ANALYSIS
           5.7.1 LIQUID BIOPSY MARKET: ROLE IN ECOSYSTEM
    5.8 PORTER’S FIVE FORCES ANALYSIS
          TABLE 5 LIQUID BIOPSY MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.8.1 THREAT FROM NEW ENTRANTS
           5.8.2 THREAT FROM SUBSTITUTES
           5.8.3 BARGAINING POWER OF BUYERS
           5.8.4 BARGAINING POWER OF SUPPLIERS
           5.8.5 DEGREE OF COMPETITION
    5.9 REGULATORY LANDSCAPE
           5.9.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    TABLE 6 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    TABLE 7 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    TABLE 8 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    TABLE 9 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    TABLE 10 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
           5.9.2 NORTH AMERICA
                    5.9.2.1 US
                    5.9.2.2 Canada
           5.9.3 EUROPE
           5.9.4 ASIA PACIFIC
                    5.9.4.1 China
                    5.9.4.2 Japan
           5.9.5 LATIN AMERICA
                    5.9.5.1 Brazil
                    5.9.5.2 Mexico
           5.9.6 MIDDLE EAST
           5.9.7 AFRICA
    5.10 TECHNOLOGY ANALYSIS
    5.11 PESTLE ANALYSIS
    5.12 TRADE ANALYSIS
           5.12.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS
                    5.12.1.1 Export scenario for liquid biopsy
                                 TABLE 11 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2017–2021 (USD MILLION)
                    5.12.1.2 Import scenario for liquid biopsy
                                 TABLE 12 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2017–2021 (USD MILLION)
                                 TABLE 13 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2017–2021 (TONS)
    5.13 KEY CONFERENCES AND EVENTS IN 2022–2023
           TABLE 14 LIQUID BIOPSY MARKET: DETAILED LIST OF CONFERENCES AND EVENTS
    5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
           5.14.1 REVENUE SHIFT & REVENUE POCKETS FOR LIQUID BIOPSY PRODUCT MANUFACTURERS
                     FIGURE 30 REVENUE SHIFT FOR LIQUID BIOPSY MARKET
    5.15 KEY STAKEHOLDERS AND BUYING CRITERIA
           5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
                     FIGURE 31 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF LIQUID BIOPSY PRODUCTS & SERVICES
                     TABLE 15 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF LIQUID BIOPSY PRODUCTS & SERVICES
           5.15.2 BUYING CRITERIA
                     FIGURE 32 KEY BUYING CRITERIA FOR LIQUID BIOPSY PRODUCTS & SERVICES
                     TABLE 16 KEY BUYING CRITERIA FOR LIQUID BIOPSY PRODUCTS & SERVICES
    5.16 CASE STUDY ANALYSIS
           5.16.1 CASE STUDY 1
           5.16.2 CASE STUDY 2

6 LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE (Page No. - 90)
    6.1 INTRODUCTION
          TABLE 17 LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
    6.2 ASSAY KITS
           6.2.1 RECURRENT REQUIREMENT AND PURCHASES OF ASSAY KITS TO DRIVE GROWTH
                    TABLE 18 KEY PRODUCTS IN ASSAY KITS MARKET
                    TABLE 19 LIQUID BIOPSY ASSAY KITS MARKET, BY REGION, 2020–2027 (USD MILLION)
    6.3 INSTRUMENTS
           6.3.1 LATEST ADVANCEMENTS IN PCR TECHNOLOGIES TO ENSURE MARKET GROWTH
                    TABLE 20 KEY PRODUCTS IN INSTRUMENTS MARKET
                    TABLE 21 LIQUID BIOPSY INSTRUMENTS MARKET, BY REGION, 2020–2027 (USD MILLION)
    6.4 SERVICES
           6.4.1 INCREASING NUMBER OF LIQUID BIOPSY-BASED SERVICE DEVELOPMENTS TO SUPPORT MARKET GROWTH
                    TABLE 22 LIQUID BIOPSY SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)

7 LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER (Page No. - 96)
    7.1 INTRODUCTION
          TABLE 23 LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2027 (USD MILLION)
    7.2 CIRCULATING TUMOR CELLS (CTC)
           7.2.1 EASY COLLECTION AND PERSISTENT ASSESSMENT & ANALYSIS OF OVERALL TUMOR BURDEN TO DRIVE DEMAND
                    TABLE 24 LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR CELLS, BY REGION, 2020–2027 (USD MILLION)
    7.3 CIRCULATING TUMOR DNA (CTDNA)
           7.3.1 ABILITY OF CTDNA ANALYSIS TO SIGNIFICANTLY IMPROVE TUMOR DIAGNOSIS TO DRIVE MARKET
                    TABLE 25 LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR DNA, BY REGION, 2020–2027 (USD MILLION)
    7.4 CELL-FREE DNA (CFDNA)
           7.4.1 GROWING APPLICATION OF CFDNA IN PRENATAL SCREENING TO DRIVE GROWTH
                    TABLE 26 LIQUID BIOPSY MARKET FOR CELL-FREE DNA, BY REGION, 2020–2027 (USD MILLION)
    7.5 EXTRACELLULAR VESICLES (EVS)
           7.5.1 ABILITY TO REMAIN STABLE IN BLOOD CIRCULATION OVER OTHER ANALYTES TO ENSURE CONSISTENT GROWTH IN MARKET
                    TABLE 27 LIQUID BIOPSY MARKET FOR EXTRACELLULAR VESICLES, BY REGION, 2020–2027 (USD MILLION)
    7.6 OTHER CIRCULATING BIOMARKERS
          TABLE 28 LIQUID BIOPSY MARKET FOR OTHER CIRCULATING BIOMARKERS, BY REGION, 2020–2027 (USD MILLION)

8 LIQUID BIOPSY MARKET, BY TECHNOLOGY (Page No. - 102)
    8.1 INTRODUCTION
          TABLE 29 LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
    8.2 MULTI-GENE PARALLEL ANALYSIS USING NGS
           8.2.1 HIGH SENSITIVITY AND ECONOMICAL BENEFITS TO DRIVE GROWTH
                    TABLE 30 LIQUID BIOPSY MARKET FOR MULTI-GENE PARALLEL ANALYSIS USING NGS, BY REGION, 2020–2027 (USD MILLION)
    8.3 SINGLE-GENE ANALYSIS USING PCR MICROARRAYS
           8.3.1 COST BENEFITS OF PCR TECHNOLOGY TO DRIVE ADOPTION
                    TABLE 31 LIQUID BIOPSY MARKET FOR SINGLE-GENE ANALYSIS USING PCR MICROARRAYS, BY REGION, 2020–2027 (USD MILLION)

9 LIQUID BIOPSY MARKET, BY APPLICATION (Page No. - 106)
    9.1 INTRODUCTION
          TABLE 32 LIQUID BIOPSY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
    9.2 CANCER APPLICATIONS
          TABLE 33 GLOBAL CANCER INCIDENCE, 2020 VS. 2040 (MILLION)
          TABLE 34 LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
          TABLE 35 LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
           9.2.1 LUNG CANCER
                    9.2.1.1 Growing prevalence of lung cancer to propel market growth
                                TABLE 36 GLOBAL LUNG CANCER INCIDENCE, 2020 VS. 2040
                                TABLE 37 LIQUID BIOPSY MARKET FOR LUNG CANCER, BY REGION, 2020–2027 (USD MILLION)
           9.2.2 BREAST CANCER
                    9.2.2.1 Increasing government funding for breast cancer research to spur growth
                                TABLE 38 GLOBAL BREAST CANCER INCIDENCE, 2020 VS. 2040
                                TABLE 39 LIQUID BIOPSY MARKET FOR BREAST CANCER, BY REGION, 2020–2027 (USD MILLION)
           9.2.3 COLORECTAL CANCER
                    9.2.3.1 Rising prevalence of colorectal cancer to propel market
                                TABLE 40 GLOBAL COLORECTAL CANCER INCIDENCE, 2020 VS. 2040
                                TABLE 41 LIQUID BIOPSY MARKET FOR COLORECTAL CANCER, BY REGION, 2020–2027 (USD MILLION)
           9.2.4 PROSTATE CANCER
                    9.2.4.1 Growing number of prostate cancer patients to support market growth
                                TABLE 42 GLOBAL PROSTATE CANCER INCIDENCE, 2020 VS. 2040
                                TABLE 43 LIQUID BIOPSY MARKET FOR PROSTATE CANCER, BY REGION, 2020–2027 (USD MILLION)
           9.2.5 MELANOMA
                    9.2.5.1 Growing need for early diagnosis of genetically mutated tumors to drive market growth
                                TABLE 44 GLOBAL MELANOMA INCIDENCE, 2020 VS. 2040
                                TABLE 45 LIQUID BIOPSY MARKET FOR MELANOMA, BY REGION, 2020–2027 (USD MILLION)
           9.2.6 OTHER CANCERS
                    TABLE 46 GLOBAL INCIDENCE OF OTHER CANCERS, 2020
                    TABLE 47 LIQUID BIOPSY MARKET FOR OTHER CANCERS, BY REGION, 2020–2027 (USD MILLION)
    9.3 NON-CANCER APPLICATIONS
          TABLE 48 LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
          TABLE 49 LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
           9.3.1 NON-INVASIVE PRENATAL TESTING (NIPT)
                    9.3.1.1 Growing demand for NIPT in high-risk pregnancies to drive growth
                                TABLE 50 LIQUID BIOPSY MARKET FOR NIPT, BY REGION, 2020–2027 (USD MILLION)
           9.3.2 ORGAN TRANSPLANTATIONS
                    9.3.2.1 Need for early detection of rejection to improve survival chances to drive growth
                                TABLE 51 LIQUID BIOPSY MARKET FOR ORGAN TRANSPLANTATIONS, BY REGION, 2020–2027 (USD MILLION)
           9.3.3 INFECTIOUS DISEASE TESTING
                    9.3.3.1 Potential to reliably identify a wide variety of infections to drive adoption
                                TABLE 52 LIQUID BIOPSY MARKET FOR INFECTIOUS DISEASE TESTING, BY REGION, 2020–2027 (USD MILLION)

10 LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION (Page No. - 122)
     10.1 INTRODUCTION
             TABLE 53 LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020–2027 (USD MILLION)
     10.2 THERAPY SELECTION
             10.2.1 GROWING PREFERENCE DUE TO NON-INVASIVENESS OF LIQUID BIOPSY TESTS TO DRIVE GROWTH
                        TABLE 54 LIQUID BIOPSY MARKET FOR THERAPY SELECTION, BY REGION, 2020–2027 (USD MILLION)
     10.3 TREATMENT MONITORING
             10.3.1 ABILITY TO QUANTITATIVELY CALCULATE CONCENTRATIONS OF CANCER-RELATED MUTATIONS TO FUEL DEMAND
                        TABLE 55 LIQUID BIOPSY MARKET FOR TREATMENT MONITORING, BY REGION, 2020–2027 (USD MILLION)
     10.4 RECURRENCE MONITORING
             10.4.1 ABILITY TO DETECT CANCER MUTATIONS THROUGH CTDNA TO DRIVE GROWTH
                        TABLE 56 LIQUID BIOPSY MARKET FOR RECURRENCE MONITORING, BY REGION, 2020–2027 (USD MILLION)
     10.5 EARLY CANCER SCREENING
             10.5.1 POTENTIAL OF LIQUID BIOPSY TO DETECT CANCER IN EARLY STAGES TO DRIVE MARKET
                        TABLE 57 LIQUID BIOPSY MARKET FOR EARLY CANCER SCREENING, BY REGION, 2020–2027 (USD MILLION)

11 LIQUID BIOPSY MARKET, BY SAMPLE TYPE (Page No. - 128)
     11.1 INTRODUCTION
             TABLE 58 LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020–2027 (USD MILLION)
             TABLE 59 LIQUID BIOPSY SAMPLES AND APPLICATIONS
     11.2 BLOOD
             11.2.1 SIMPLE AND NON-INVASIVE NATURE TO DRIVE MARKET GROWTH
                        TABLE 60 LIQUID BIOPSY MARKET FOR BLOOD SAMPLES, BY REGION, 2020–2027 (USD MILLION)
     11.3 OTHER SAMPLE TYPES
             TABLE 61 LIQUID BIOPSY MARKET FOR OTHER SAMPLE TYPES, BY REGION, 2020–2027 (USD MILLION)

12 LIQUID BIOPSY MARKET, BY END USER (Page No. - 132)
     12.1 INTRODUCTION
             TABLE 62 LIQUID BIOPSY MARKET, BY END USER, 2020–2027 (USD MILLION)
     12.2 REFERENCE LABORATORIES
             12.2.1 INCREASING OUTSOURCING OF LIQUID BIOPSY TESTS TO REFERENCE LABORATORIES TO DRIVE GROWTH
                        TABLE 63 LIQUID BIOPSY MARKET FOR REFERENCE LABORATORIES, BY REGION, 2020–2027 (USD MILLION)
     12.3 HOSPITALS AND PHYSICIAN LABORATORIES
             12.3.1 GROWING NUMBER OF HOSPITALS WORLDWIDE TO BOOST GROWTH
                        TABLE 64 LIQUID BIOPSY MARKET FOR HOSPITALS AND PHYSICIAN LABORATORIES, BY REGION, 2020–2027 (USD MILLION)
     12.4 ACADEMIC & RESEARCH CENTERS
             12.4.1 GROWING FOCUS OF RESEARCH FOR DEVELOPMENT OF INNOVATIVE LIQUID BIOPSY TESTS TO FUEL GROWTH
                        TABLE 65 LIQUID BIOPSY MARKET FOR ACADEMIC & RESEARCH CENTERS, BY REGION, 2020–2027 (USD MILLION)
     12.5 OTHER END USERS
             TABLE 66 LIQUID BIOPSY MARKET FOR OTHER END USERS, BY REGION, 2020–2027 (USD MILLION)

13 LIQUID BIOPSY MARKET, BY REGION (Page No. - 137)
     13.1 INTRODUCTION
             TABLE 67 LIQUID BIOPSY MARKET, BY REGION, 2020–2027 (USD MILLION)
     13.2 NORTH AMERICA
             TABLE 68 NORTH AMERICA: NUMBER OF NEW CANCER CASES, BY TYPE OF CANCER, 2020
             FIGURE 33 NORTH AMERICA: LIQUID BIOPSY MARKET SNAPSHOT
             TABLE 69 NORTH AMERICA: LIQUID BIOPSY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
             TABLE 70 NORTH AMERICA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
             TABLE 71 NORTH AMERICA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2027 (USD MILLION)
             TABLE 72 NORTH AMERICA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
             TABLE 73 NORTH AMERICA: LIQUID BIOPSY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
             TABLE 74 NORTH AMERICA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020–2027 (USD MILLION)
             TABLE 75 NORTH AMERICA: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020–2027 (USD MILLION)
             TABLE 76 NORTH AMERICA: LIQUID BIOPSY MARKET, BY END USER, 2020–2027 (USD MILLION)
             13.2.1 US
                        13.2.1.1 Increasing prevalence of cancer to drive growth
                                      TABLE 77 US: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
                                      TABLE 78 US: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2027 (USD MILLION)
                                      TABLE 79 US: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 80 US: LIQUID BIOPSY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 81 US: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 82 US: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020–2027 (USD MILLION)
                                      TABLE 83 US: LIQUID BIOPSY MARKET, BY END USER, 2020–2027 (USD MILLION)
             13.2.2 CANADA
                        13.2.2.1 Availability of various cancer screening programs to drive growth
                                      TABLE 84 CANADA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
                                      TABLE 85 CANADA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2027 (USD MILLION)
                                      TABLE 86 CANADA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 87 CANADA: LIQUID BIOPSY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 88 CANADA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 89 CANADA: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020–2027 (USD MILLION)
                                      TABLE 90 CANADA: LIQUID BIOPSY MARKET, BY END USER, 2020–2027 (USD MILLION)
     13.3 EUROPE
             TABLE 91 EUROPE: LIQUID BIOPSY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
             TABLE 92 EUROPE: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
             TABLE 93 EUROPE: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2027 (USD MILLION)
             TABLE 94 EUROPE: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
             TABLE 95 EUROPE: LIQUID BIOPSY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
             TABLE 96 EUROPE: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020–2027 (USD MILLION)
             TABLE 97 EUROPE: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020–2027 (USD MILLION)
             TABLE 98 EUROPE: LIQUID BIOPSY MARKET, BY END USER, 2020–2027 (USD MILLION)
             13.3.1 GERMANY
                        13.3.1.1 Favorable government health policies to support market growth
                                      TABLE 99 GERMANY: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
                                      TABLE 100 GERMANY: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2027 (USD MILLION)
                                      TABLE 101 GERMANY: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 102 GERMANY: LIQUID BIOPSY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 103 GERMANY: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 104 GERMANY: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020–2027 (USD MILLION)
                                      TABLE 105 GERMANY: LIQUID BIOPSY MARKET, BY END USER, 2020–2027 (USD MILLION)
             13.3.2 UK
                        13.3.2.1 Increasing number of diagnostic laboratories to propel market growth
                                      TABLE 106 UK: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
                                      TABLE 107 UK: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2027 (USD MILLION)
                                      TABLE 108 UK: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 109 UK: LIQUID BIOPSY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 110 UK: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 111 UK: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020–2027 (USD MILLION)
                                      TABLE 112 UK: LIQUID BIOPSY MARKET, BY END USER, 2020–2027 (USD MILLION)
             13.3.3 FRANCE
                        13.3.3.1 Rising R&D expenditure to drive market growth
                                      TABLE 113 FRANCE: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
                                      TABLE 114 FRANCE: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2027 (USD MILLION)
                                      TABLE 115 FRANCE: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 116 FRANCE: LIQUID BIOPSY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 117 FRANCE: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 118 FRANCE: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020–2027 (USD MILLION)
                                      TABLE 119 FRANCE: LIQUID BIOPSY MARKET, BY END USER, 2020–2027 (USD MILLION)
             13.3.4 ITALY
                        13.3.4.1 Growing research on discovery of novel circulating cancer biomarkers to drive market growth
                                      TABLE 120 ITALY: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
                                      TABLE 121 ITALY: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2027 (USD MILLION)
                                      TABLE 122 ITALY: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 123 ITALY: LIQUID BIOPSY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 124 ITALY: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 125 ITALY: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020–2027 (USD MILLION)
                                      TABLE 126 ITALY: LIQUID BIOPSY MARKET, BY END USER, 2020–2027 (USD MILLION)
             13.3.5 SPAIN
                        13.3.5.1 Growing focus on personalized medicine to support market growth
                                      TABLE 127 SPAIN: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
                                      TABLE 128 SPAIN: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2027 (USD MILLION)
                                      TABLE 129 SPAIN: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 130 SPAIN: LIQUID BIOPSY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 131 SPAIN: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 132 SPAIN: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020–2027 (USD MILLION)
                                      TABLE 133 SPAIN: LIQUID BIOPSY MARKET, BY END USER, 2020–2027 (USD MILLION)
             13.3.6 REST OF EUROPE
                        TABLE 134 REST OF EUROPE: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
                        TABLE 135 REST OF EUROPE: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2027 (USD MILLION)
                        TABLE 136 REST OF EUROPE: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                        TABLE 137 REST OF EUROPE: LIQUID BIOPSY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                        TABLE 138 REST OF EUROPE: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020–2027 (USD MILLION)
                        TABLE 139 REST OF EUROPE: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020–2027 (USD MILLION)
                        TABLE 140 REST OF EUROPE: LIQUID BIOPSY MARKET, BY END USER, 2020–2027 (USD MILLION)
     13.4 ASIA PACIFIC
             FIGURE 34 ASIA PACIFIC: LIQUID BIOPSY MARKET SNAPSHOT
             TABLE 141 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
             TABLE 142 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
             TABLE 143 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2027 (USD MILLION)
             TABLE 144 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
             TABLE 145 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
             TABLE 146 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020–2027 (USD MILLION)
             TABLE 147 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020–2027 (USD MILLION)
             TABLE 148 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY END USER, 2020–2027 (USD MILLION)
             13.4.1 CHINA
                        13.4.1.1 Growing public access to advanced healthcare facilities to drive market
                                      TABLE 149 CHINA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
                                      TABLE 150 CHINA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2027 (USD MILLION)
                                      TABLE 151 CHINA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 152 CHINA: LIQUID BIOPSY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 153 CHINA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 154 CHINA: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020–2027 (USD MILLION)
                                      TABLE 155 CHINA: LIQUID BIOPSY MARKET, BY END USER, 2020–2027 (USD MILLION)
             13.4.2 JAPAN
                        13.4.2.1 Universal healthcare reimbursement policy to fuel growth
                                      TABLE 156 JAPAN: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
                                      TABLE 157 JAPAN: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2027 (USD MILLION)
                                      TABLE 158 JAPAN: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 159 JAPAN: LIQUID BIOPSY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 160 JAPAN: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 161 JAPAN: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020–2027 (USD MILLION)
                                      TABLE 162 JAPAN: LIQUID BIOPSY MARKET, BY END USER, 2020–2027 (USD MILLION)
             13.4.3 INDIA
                        13.4.3.1 Increasing private & public investments in healthcare system to boost market
                                      TABLE 163 INDIA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
                                      TABLE 164 INDIA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2027 (USD MILLION)
                                      TABLE 165 INDIA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 166 INDIA: LIQUID BIOPSY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 167 INDIA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 168 INDIA: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020–2027 (USD MILLION)
                                      TABLE 169 INDIA: LIQUID BIOPSY MARKET, BY END USER, 2020–2027 (USD MILLION)
             13.4.4 REST OF ASIA PACIFIC
                        TABLE 170 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
                        TABLE 171 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2027 (USD MILLION)
                        TABLE 172 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                        TABLE 173 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                        TABLE 174 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020–2027 (USD MILLION)
                        TABLE 175 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020–2027 (USD MILLION)
                        TABLE 176 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY END USER, 2020–2027 (USD MILLION)
     13.5 LATIN AMERICA
             13.5.1 INCREASING PRIVATE & PUBLIC INVESTMENTS TO DRIVE MARKET
                        TABLE 177 LATIN AMERICA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
                        TABLE 178 LATIN AMERICA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2027 (USD MILLION)
                        TABLE 179 LATIN AMERICA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                        TABLE 180 LATIN AMERICA: LIQUID BIOPSY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                        TABLE 181 LATIN AMERICA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020–2027 (USD MILLION)
                        TABLE 182 LATIN AMERICA: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020–2027 (USD MILLION)
                        TABLE 183 LATIN AMERICA: LIQUID BIOPSY MARKET, BY END USER, 2020–2027 (USD MILLION)
     13.6 MIDDLE EAST & AFRICA
             13.6.1 INCREASING FUNDING IN RESEARCH TO DRIVE MARKET GROWTH
                        TABLE 184 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
                        TABLE 185 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2027 (USD MILLION)
                        TABLE 186 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                        TABLE 187 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                        TABLE 188 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020–2027 (USD MILLION)
                        TABLE 189 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020–2027 (USD MILLION)
                        TABLE 190 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY END USER, 2020–2027 (USD MILLION)

14 COMPETITIVE LANDSCAPE (Page No. - 195)
     14.1 OVERVIEW
     14.2 STRATEGIES OF KEY PLAYERS
             14.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN LIQUID BIOPSY MARKET
                        TABLE 191 OVERVIEW OF STRATEGIES DEPLOYED BY KEY LIQUID BIOPSY COMPANIES
     14.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
             FIGURE 35 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN LIQUID BIOPSY MARKET
     14.4 MARKET SHARE ANALYSIS
             14.4.1 LIQUID BIOPSY MARKET
                        FIGURE 36 LIQUID BIOPSY MARKET SHARE, BY KEY PLAYER (2021)
                        TABLE 192 LIQUID BIOPSY MARKET SHARE: DEGREE OF COMPETITION
     14.5 COMPANY EVALUATION QUADRANT
             14.5.1 LIST OF EVALUATED VENDORS
             14.5.2 STARS
             14.5.3 EMERGING LEADERS
             14.5.4 PERVASIVE PLAYERS
             14.5.5 PARTICIPANTS
                        FIGURE 37 LIQUID BIOPSY MARKET: COMPETITIVE LEADERSHIP MAPPING, 2021
     14.6 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES (2021)
             14.6.1 PROGRESSIVE COMPANIES
             14.6.2 STARTING BLOCKS
             14.6.3 RESPONSIVE COMPANIES
             14.6.4 DYNAMIC COMPANIES
                        FIGURE 38 LIQUID BIOPSY MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES, 2021
     14.7 COMPETITIVE BENCHMARKING
             14.7.1 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS
                        FIGURE 39 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS OF TOP PLAYERS IN LIQUID BIOPSY MARKET
                        TABLE 193 LIQUID BIOPSY MARKET: COMPANY GEOGRAPHICAL FOOTPRINT
                        TABLE 194 LIQUID BIOPSY MARKET: COMPANY PRODUCT & SERVICE FOOTPRINT
                        TABLE 195 LIQUID BIOPSY MARKET: DETAILED LIST OF KEY START-UPS/SMES
     14.8 COMPETITIVE SCENARIO
             14.8.1 PRODUCT LAUNCHES & APPROVALS
                        TABLE 196 KEY PRODUCT LAUNCHES & APPROVALS
             14.8.2 DEALS
                        TABLE 197 KEY DEALS

15 COMPANY PROFILES (Page No. - 208)
(Business overview, Products offered, Recent Developments, MNM view)*
     15.1 KEY PLAYERS
             15.1.1 QIAGEN N.V.
                        TABLE 198 QIAGEN N.V.: BUSINESS OVERVIEW
                        FIGURE 40 QIAGEN N.V.: COMPANY SNAPSHOT (2021)
             15.1.2 F. HOFFMANN-LA ROCHE AG
                        TABLE 199 F. HOFFMANN-LA ROCHE AG: BUSINESS OVERVIEW
                        FIGURE 41 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2021)
             15.1.3 MYRIAD GENETICS, INC.
                        TABLE 200 MYRIAD GENETICS, INC.: BUSINESS OVERVIEW
                        FIGURE 42 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2021)
             15.1.4 THERMO FISHER SCIENTIFIC, INC.
                        TABLE 201 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
                        FIGURE 43 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2021)
             15.1.5 GUARDANT HEALTH, INC.
                        TABLE 202 GUARDANT HEALTH, INC.: BUSINESS OVERVIEW
                        FIGURE 44 GUARDANT HEALTH, INC.: COMPANY SNAPSHOT (2021)
             15.1.6 BIO-RAD LABORATORIES, INC.
                        TABLE 203 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
                        FIGURE 45 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2021)
             15.1.7 ILLUMINA, INC.
                        TABLE 204 ILLUMINA, INC.: BUSINESS OVERVIEW
                        FIGURE 46 ILLUMINA, INC.: COMPANY SNAPSHOT (2021)
             15.1.8 EXACT SCIENCES CORPORATION
                        TABLE 205 EXACT SCIENCES CORPORATION: BUSINESS OVERVIEW
                        FIGURE 47 EXACT SCIENCES CORPORATION: COMPANY SNAPSHOT (2021)
             15.1.9 SYSMEX INOSTICS (SUBSIDIARY OF SYSMEX CORPORATION)
                        TABLE 206 SYSMEX INOSTICS: BUSINESS OVERVIEW
                        FIGURE 48 SYSMEX CORPORATION: COMPANY SNAPSHOT (2021)
             15.1.10 BIOCEPT, INC.
                        TABLE 207 BIOCEPT, INC.: BUSINESS OVERVIEW
                        FIGURE 49 BIOCEPT, INC.: COMPANY SNAPSHOT (2021)
             15.1.11 MDXHEALTH
                        TABLE 208 MDXHEALTH: BUSINESS OVERVIEW
                        FIGURE 50 MDXHEALTH: COMPANY SNAPSHOT (2021)
     15.2 OTHER PLAYERS
             15.2.1 NEOGENOMICS, INC.
             15.2.2 EPIGENOMICS AG
             15.2.3 ANGLE PLC
             15.2.4 MENARINI-SILICON BIOSYSTEMS
             15.2.5 VORTEX BIOSCIENCES, INC.
             15.2.6 EXOSOME DIAGNOSTICS, INC.
             15.2.7 MEDGENOME INC.
             15.2.8 AGENA BIOSCIENCE, INC.
             15.2.9 PERSONAL GENOME DIAGNOSTICS, INC.
             15.2.10 FREENOME HOLDINGS, INC.
             15.2.11 STRAND LIFE SCIENCES
             15.2.12 LUNGLIFE AI, INC.
             15.2.13 LUCENCE HEALTH INC.
             15.2.14 ANPAC BIO-MEDICAL SCIENCE CO., LTD.

*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.

16 APPENDIX (Page No. - 263)
     16.1 DISCUSSION GUIDE
     16.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     16.3 CUSTOMIZATION OPTIONS
     16.4 RELATED REPORTS
     16.5 AUTHOR DETAILS